Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 4/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12223510 | 1.00 | GPR119 (0.34) | GPR119ALOX5APFEN1ACACBCNR2 | |
| SCHEMBL12224684 | 0.93 | GPR119 (0.36) | GPR119ACACBCNR2SCN9AHCRTR2 | |
| SCHEMBL12224680 | 0.93 | GPR119 (0.36) | GPR119ACACBCNR2SCN9AHCRTR2 | |
| SCHEMBL11939325 | 0.93 | CNR2 (0.36) | ALOX5APFEN1CNR2CNR1SCN9A | |
| SCHEMBL11939353 | 0.93 | CNR2 (0.36) | ALOX5APFEN1CNR2CNR1SCN9A | |
| SCHEMBL11939128 | 0.91 | FPR2 (0.34) | ALOX5APFEN1ACACBFPR2 | |
| SCHEMBL12223996 | 0.90 | GPR119 (0.34) | GPR119ALOX5APFEN1ACACBHCRTR2 | |
| SCHEMBL12223906 | 0.90 | CNR2 (0.34) | ALOX5APFEN1CNR2CNR1SCN9A | |
| SCHEMBL12224646 | 0.90 | GPR119 (0.34) | GPR119ALOX5APFEN1ACACBHCRTR2 | |
| SCHEMBL12223307 | 0.90 | FPR2 (0.32) | ALOX5APFEN1CNR2FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110240919-A1 | FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NCAPD3, CCND3, ZKSCAN2 | GPR119 4269/4885ALOX5AP 1073/4885FEN1 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.